Seeing Is Believing
Currently out of the existing stock ratings of Marc Goodman, 186 are a BUY (77.18%), 49 are a HOLD (20.33%), 6 are a SELL (2.49%).
Analyst Marc Goodman, currently employed at LEERINK, carries an average stock price target met ratio of 59.13% that have a potential upside of 34.27% achieved within 335 days.
Marc Goodman’s has documented 438 price targets and ratings displayed on 44 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on AMLX, Amylyx Pharmaceuticals at 06-May-2025.
Analyst best performing recommendations are on KRTX (KARUNA THERAPEUTICS).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $270 was fulfilled within 3 days with a profit of $41.55 (18.19%) receiving and performance score of 60.63.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$284
$53.5 (23.21%)
$220
6 days ago
(10-Oct-2025)
43/44 (97.73%)
$53.5 (23.21%)
593
Hold
$251
$20.5 (8.89%)
$205
13 days ago
(03-Oct-2025)
15/16 (93.75%)
$17.09 (7.31%)
300
Buy
$270
$39.5 (17.14%)
$195
29 days ago
(17-Sep-2025)
2/3 (66.67%)
$49.19 (22.28%)
121
Buy
$235
$4.5 (1.95%)
$200
1 months ago
(16-Sep-2025)
14/14 (100%)
$18.74 (8.67%)
483
Buy
$245
$14.5 (6.29%)
$210
1 months 1 days ago
(15-Sep-2025)
16/17 (94.12%)
$27.39 (12.59%)
244
Which stock is Marc Goodman is most bullish on?
What Year was the first public recommendation made by Marc Goodman?